Sugi Predict

Sugi Predict / Compounds / SCHEMBL16992195

SCHEMBL16992195

SCHEMBL16992195

CC(C)N1CC[C](F)CC1

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ CHRNA7 P36544 1/20 0.50
▸ HRH3 Q9Y5N1 4/20 0.35
▸ ALDH1A1 P00352 3/20 0.34
▸ KDM4E B2RXH2 2/20 0.34
▸ MAPT P10636 2/20 0.34
▸ PKM P14618 1/20 0.34
▸ CYP2D6 P10635 1/20 0.34
▸ GAA P10253 3/20 0.32
▸ THRB P10828 1/20 0.32
▸ L3MBTL1 Q9Y468 1/20 0.32
▸ LMNA P02545 1/20 0.31
▸ PTPN2 P17706 1/20 0.30
▸ MEN1 O00255 1/20 0.30
▸ HPGD P15428 1/20 0.30
▸ KMT2A Q03164 1/20 0.30
▸ SMN1; SMN2 Q16637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19459142 0.74 CHRNA7 (0.52) CHRNA7HRH3ALDH1A1KDM4EMAPT
SCHEMBL19459119 0.74 CHRNA7 (0.46) CHRNA7HRH3ALDH1A1KDM4EMAPT
SCHEMBL23980754 0.73 CHRNA7 (0.44) CHRNA7HRH3ALDH1A1KDM4EMAPT
SCHEMBL19459064 0.72 CHRNA7 (0.56) CHRNA7HRH3ALDH1A1KDM4EMAPT
SCHEMBL190568 0.72 CHRNA7 (0.50) CHRNA7HRH3ALDH1A1KDM4EMAPT
SCHEMBL15505237 0.72 CHRNA7 (0.50) CHRNA7HRH3ALDH1A1KDM4EMAPT
SCHEMBL10130728 0.72 CHRNA7 (0.50) CHRNA7HRH3ALDH1A1KDM4EMAPT
SCHEMBL24733236 0.72 CHRNA7 (0.41) CHRNA7HRH3ALDH1A1KDM4EMAPT
SCHEMBL13290568 0.71 CHRNA7 (0.46) CHRNA7HRH3ALDH1A1KDM4EMAPT
SCHEMBL681912 0.71 CHRNA7 (0.46) CHRNA7HRH3ALDH1A1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3442977-B1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORP (US) 2023-06-28 — — EP claimed
CN-109311889-B Activin receptor-like kinase inhibitors 缆图药品公司 2021-11-16 — — CN claimed
EP-3442977-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE Blueprint Medicines Corporation (US) 2019-02-20 — — EP claimed
WO-2017181117-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORPORATION (US) 2017-10-19 — — WO claimed
US-20240158398-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORPORATION 2024-05-16 — — US disclosed
EP-4285996-A2 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE Blueprint Medicines Corporation (US) 2023-12-06 — — EP disclosed
US-11786524-B2 Pharmaceutical compounds SENTINEL ONCOLOGY LIMITED (GB) 2023-10-17 — — US disclosed
EP-3442977-B1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORP (US) 2023-06-28 — — EP disclosed
US-11634422-B2 Inhibitors of activin receptor-like kinase BLUEPRINT MEDICINES CORPORATION (US) 2023-04-25 — — US disclosed
CN-109311889-B Activin receptor-like kinase inhibitors 缆图药品公司 2021-11-16 — — CN disclosed
US-20210275525-A1 PHARMACEUTICAL COMPOUNDS SENTINEL ONCOLOGY LIMITED (GB) 2021-09-09 — — US disclosed
EP-3811944-A1 PHARMACEUTICAL COMPOUNDS AS CHK1 INHIBITORS Sentinel Oncology Limited (GB) 2021-04-28 — — EP disclosed
US-20180271860-A1 PHARMACEUTICAL COMPOUNDS CASCADIAN THERAPEUTICS, INC. (US) 2018-09-27 — — US disclosed
US-10010547-B2 Pharmaceutical compounds CASCADIAN THERAPEUTICS, INC. (US) 2018-07-03 — — US disclosed
US-20170298069-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORPORATION 2017-10-19 — — US disclosed
WO-2017181117-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORPORATION (US) 2017-10-19 — — WO disclosed
EP-3104860-A1 PHARMACEUTICAL COMPOUNDS Cascadian Therapeutics, Inc. (US) 2016-12-21 — — EP disclosed
US-20160361310-A1 PHARMACEUTICAL COMPOUNDS SEATTLE GENETICS, INC. 2016-12-15 — — US disclosed
CN-106170288-A Pharmaceutical compounds 卡斯卡迪安疗法公司 2016-11-30 — — CN disclosed
WO-2015120390-A1 PHARMACEUTICAL COMPOUNDS ONCOTHYREON INC. (US) 2015-08-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240158398-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE ACVR1, ACVR2A, ACVRL1 CHRNA7 1308/4885HRH3 2428/4885ALDH1A1 3277/4885
US-10010547-B2 Pharmaceutical compounds CHKA, CHKB, TNK2 CHRNA7 2213/4885HRH3 1262/4885ALDH1A1 4266/4885
US-20180271860-A1 PHARMACEUTICAL COMPOUNDS CHKA, CHKB, TNK2 CHRNA7 2213/4885HRH3 1262/4885ALDH1A1 4266/4885
US-11634422-B2 Inhibitors of activin receptor-like kinase ACVR1, ACVR2A, ACVRL1 CHRNA7 1308/4885HRH3 2428/4885ALDH1A1 3277/4885
US-11786524-B2 Pharmaceutical compounds CHKA, CHKB, TNK2 CHRNA7 2213/4885HRH3 1262/4885ALDH1A1 4266/4885
US-20160361310-A1 PHARMACEUTICAL COMPOUNDS CHKA, CHKB, TNK2 CHRNA7 2213/4885HRH3 1262/4885ALDH1A1 4266/4885
US-20210275525-A1 PHARMACEUTICAL COMPOUNDS CHKA, CHKB, TNK2 CHRNA7 2213/4885HRH3 1262/4885ALDH1A1 4266/4885
US-20170298069-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE ACVR1, ACVR2A, ACVRL1 CHRNA7 1308/4885HRH3 2428/4885ALDH1A1 3277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.